Biótica has earned Performance Tested Method approval from the AOAC Research Institute for its Legipid® Bioalarm Legionella for detection of Legionella pneumophila in waters. The approval was granted after extensive independent evaluation.
Biótica’s newly-approved test for Legionella pneumophila (AOAC-RI 111101) is a fast, economic and simple immuno-magnetic analysis that revolutionizes the risk assessement of this pathogenic bacterium in water bodies.
The Valencian region’s push in biotechnology has created very fertile ground for outside investment in the numerous spin-offs and start ups. One of the objectives for Bioval is to identify the innovative ideas and business opportunities based in Biotechnology to provide alternatives to traditional investment options. Grow with Biotechnolgy. More information.
The biotechnology sector in the Valencian Region is already composed of a diverse mix of companies, ranging from multinational sector leaders, to innovative start up companies beginning to make their mark. The diversity of these companies is further expounded by the broad range of biotech projects.
Celeromics is introducing Simple Counter, the first microscope automated cell counter that adapts to any optical microscope. Thanks to its state-of-the-art image analysis technology, Simple Counter turns any microscope into an automated cell counter.
Simple counter reduces lab disposable material expense, reagents expense, counting time and eye fatigue ; it has a wider counting range than alternative methods, and delivers accurate and reproducible results.
The Skin Research Platform (SRP) is a public-private joint initiative leaded by the Molecular and Cellular Biology Institute of University Miguel Hernández that aims to blend together the excellence of university research and the private sector competence for creating innovation and to develop added value dermatological products and technologies.
The skin has been traditionally a neglected field of research. Currently, it represents an expanding field for innovation, especially because skin pathologies are rising at a surprising rate but the drug arsenal is limited to old molecules and products.
Made up of a human team of more than 700 professionals and 60 research groups, the Centre for Biomedical Network Research on Rare Diseases (CIBERER) is the reference centre in Spain investigating on rare diseases. Its main objective is to favour that the research developed in the laboratories reaches out the patients.
CIBERER is the reference centre in Spain investigating on rare diseases. Its main objective is to coordinate and foster basic biomedical, clinical and epidemiological research, as well as to favour that the research developed in the laboratories reaches out the patient, giving scientific answers to the questions that arise in the interaction process between the doctor and the patient. Moreover, CIBERER’S efforts are addressed to build bridges and cooperate with other research centres and with the pharmaceutical and biotechnological industry.
